Study shows that Libtayo plus chemotherapy has lower cost and a larger effect on improving quality-adjusted life years than ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Survivors of blood or marrow transplant had increased risk for subsequent cutaneous malignant neoplasms. Basal cell carcinoma occurred more frequently than squamous cell carcinoma or melanoma.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Researchers Shed Light on How to Predict Which Skin Cancer Patients Are Most Likely to Respond to Immunotherapy Jan. 8, 2025 — An international team of UK and US scientists discovered that the ...

More growth potential is possible as the company pointed to positive data posted for adjuvant use of Libtayo in patients with cutaneous squamous cell carcinoma (CSCC). With that result ...

Read more here. Body lotion benefits your legs, knees, arms, butt, and torso in much the same way that a daily moisturizer benefits the skin on your face. According to dermatologist Dr. Heidi ...